The Altered Pharmaceutical Thought Leader Pool: How the Implementation of the Sunshine Act and CMS Open Payment Program Changed the KOL Landscape Since the adoption of the Sunshine Act in 2010 and the subsequent thought leaders’ payments reporting on the CMS Open Payment Program in 2014, many things have changed for pharmaceutical companies. It took [...]
There’s a category of thought leader that has long been overlooked, but the data now suggests companies can no longer afford to do so—that category is the Non-MD category of Nurse Practitioners (NP) and Physician Assistants (PA). From our contacts in continuing medical education (CME), we’ve heard there has been a marked increase in the [...]
Recent research shows KOL lifecycle involvement. There are a significant number of surveyed organizations – 39%, as shown in the figure below – reported that initial engagements with thought leaders start during phase 3 of a product’s lifecycle. Two percent begin at launch, but starting to cultivate thought leader relationships so late in a product [...]
Research shows what European KOLs think of MSLs they interact with. Through the deployment of scientific field teams (MSLs), organizations’ intentions are to share medical and clinical knowledge of products with the thought leaders who in turn can spread the information to physician communities and ultimately enhance patient experiences. In the process, thought leaders become [...]
Diversifying the MSL-KOL Relationships: The Emerging Pharmacist KOLs Thought leaders are critical to the life science environment, ensuring that pharmaceutical organizations inform physicians and patients about products’ uses, outcomes and benefits. Because of reporting regulations implemented in the last decade, medical affairs executives and medical field teams must now recruit and establish working relationships from [...]
The Instagram stars of therapeutic areas and disease management, Digital Opinion Influencers (DOIs) are a growing online presence that often can as effectively communicate and advocate for pharmaceutical solutions and products as Key Opinion Leaders (KOLs) do in more traditional channels (publications, conference presentations, perhaps even treating patients). The possibility of that very comparison makes [...]
Let's talk real world science! Leveraging real-world data and scientific evidence when making strategic decisions has never been more important—in the pharmaceutical world, at least. Though done here most convincingly, Arx Research isn’t the only research firm to notice and empirically confirm that physicians and thought leaders by and large want their discussions with pharma [...]
Intending to engage thought leaders is one thing, succeeding is another. The difficulty to access KOLs is based on a number of factors. First, there is the level of influence a KOL may have. Internationally recognized thought leaders are always more difficult to engage with than local influencers. KOL access will also vary based on the type of KOL [...]
The life of a MSL will vary over time and consist of many activities that are often driven by a product’s lifecycle and what management wants to focus on. We grouped some of the tasks in the graphic above to make it readable – as there are many more activities to account for. The graphic [...]
What KOLs think of MSLs? The good news is that everyone is doing a fairly good job! The bad news is…well there isn’t much bad news here. It seems KOLs really appreciate MSLs, maybe with just a few that don’t excel but no real bad apples! Overall ranking assessment of the quality of the relationships [...]
